SCHEMBL1775324

SCHEMBL1775324

Fc1ccc(COCc2cccc3ncc4nc5n(c4c23)CCOC5)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.36
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 5/20 0.34
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 3/20 0.34
CYP2C9 P11712 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C19 P33261 3/20 0.34
USP2 O75604 3/20 0.34
CASP1 P29466 3/20 0.34
HSD17B10 Q99714 3/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
BRCA1 P38398 1/20 0.34
TP53 P04637 5/20 0.32
MAPT P10636 3/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707666 0.91 GRM5 (0.40) GRM5KDM4EL3MBTL1CYP1A2ALDH1A1
SCHEMBL2244245 0.84 DCPS (0.34) GRM5KDM4EL3MBTL1
SCHEMBL4705375 0.81 GRM5 (0.33) GRM5KDM4EL3MBTL1MAPK1LMNA
SCHEMBL4707031 0.79 LMNA (0.38) GRM5KDM4EALDH1A1HSD17B10HPGD
SCHEMBL1776124 0.75 GRM5 (0.36) GRM5KDM4EL3MBTL1ALDH1A1TP53
SCHEMBL4710518 0.71 POLB (0.34) GRM5ALDH1A1KMT2AUSP2TSHR
SCHEMBL4705810 0.71 ALDH1A1 (0.36) GRM5KDM4ECYP1A2ALDH1A1MEN1
SCHEMBL4704785 0.68 POLB (0.33) GRM5ALDH1A1USP2HSD17B10MAPK1
SCHEMBL311936 0.67 PRKDC (0.45) GRM5ALDH1A1CYP3A4TP53MAPT
SCHEMBL1775257 0.67 MAPK10 (0.34) GRM5KDM4EL3MBTL1CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 US disclosed
EP-1831226-A4 CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2008-11-05 EP disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 US disclosed
EP-1831226-A2 CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-12 EP disclosed
WO-2006074003-A2 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 GRM5 2061/4885KDM4E 3100/4885L3MBTL1 2937/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 GRM5 2061/4885KDM4E 3100/4885L3MBTL1 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.